|
Jul 16
|
Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse
|
|
Jul 16
|
ENSC Start Phase 3 Trial on Abuse-Resistant Pain Reliever
|
|
Jun 24
|
Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2
|
|
Jun 11
|
Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025
|
|
May 14
|
ENSC is Moving Closer to Changing the Pain Relief Market
|
|
May 13
|
Ensysce Biosciences Reports First Quarter 2025 Financial Results
|
|
May 12
|
Ensysce Biosciences Bolsters Management Team with Regulatory Expert
|
|
Mar 13
|
Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)
|
|
Mar 12
|
Ensysce Biosciences Full Year 2024 Earnings: Beats Expectations
|
|
Mar 11
|
ENSC Starts 2025 in Great Shape
|
|
Mar 10
|
Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results
|
|
Mar 5
|
Ensysce Biosciences to Participate in the 37th Annual ROTH Conference
|
|
Mar 3
|
Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids
|
|
Jan 22
|
Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR
|
|
Jan 22
|
ENSC Continues to Announce Potential Life-Changing Results
|
|
Oct 8
|
Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit
|
|
Sep 13
|
Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024
|
|
Jul 23
|
Ensysce Biosciences Provides Mid-Year 2024 Update
|
|
Jun 25
|
Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate
|
|
Jun 6
|
Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program
|